Home

JOHN F THERO

CIK 1199637 · President and CEO · last filed 2024-02-12

JOHN F THERO is a President and CEO who has filed 84 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing shows the insider exercised options covering $21.7K of CYT on Feb 12, 2024. Across all open-market trades the lifetime net is −$42.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.3M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$2.31M

Companies

6

Total Filings

84

Lifetime Open-Market Net

-$42.43M

Filer Profile

Reported Address
C/O AMARIN PHARMA, INC.
1430 ROUTE 6
BEDMINSTER, NJ 07921
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Cyteir Therapeutics, Inc. (CYT) Delisted Director 22,828 $3.02 $68.9K $20.0K 4 2024-02-12
CinCor Pharma, Inc. (CINC) Delisted Director — $29.06 — $0 1 2023-02-24
CHIASMA, INC (CHMA) Delisted Director — $3.76 — $0 7 2021-08-05
AMRN President and CEO 162,157 $14.25 $2.31M -$42.45M 69 2021-08-03
ACUSPHERE INC (ACUS) Delisted Senior VP/CFO 91,504 — — $0 2 2007-09-06
VIACELL INC (VIAC) Delisted Sr.VP, Chief Financial Officer — $29.58 — $0 1 2007-07-02

Recent Filings

84 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2024-02-12 Cyteir Therapeutics, Inc. (CYT) Delisted Exer (M) +12,828 $21.7K EDGAR
2023-02-24 CinCor Pharma, Inc. (CINC) Delisted Disp (D) — $0 EDGAR
2023-02-07 Cyteir Therapeutics, Inc. (CYT) Delisted Grant (A) — $0 EDGAR
2022-05-12 Cyteir Therapeutics, Inc. (CYT) Delisted Buy (P) +10,000 $20.0K EDGAR
2022-02-07 Cyteir Therapeutics, Inc. (CYT) Delisted Grant (A) — $0 EDGAR
2021-08-05 CHIASMA, INC (CHMA) Delisted Disp (D) — $0 EDGAR
2021-08-03 AMRN Mixed +16,340 -$43.9K EDGAR
2021-07-02 AMRN Mixed +16,340 -$47.5K EDGAR
2021-05-28 AMRN Mixed +16,340 -$48.1K EDGAR
2021-04-30 AMRN Mixed +16,340 -$55.6K EDGAR
Showing 1–10 of 84
Page 1 of 9
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.